Navigation Links
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 15 patients have been enrolled into the Phase II portion of the study. Given the favourable biological activity and safety data, the Company intends to expand the present program from 60 to 120 patients at up to six centers in the United States, Canada and Australia, subject to regulatory approval. Detailed safety and activity data for CYT387 are planned to be presented at the American Society of Hematology (ASH) meeting in Orlando, Florida in December this year.

Myelofibrosis is a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory due to both efficacy and safety concerns.

Dosing in the Phase I dose-escalation portion of the study commenced in November 2009. In total, 21 patients were treated across five dosing levels (100, 150, 200, 300 and 400mg daily for up to nine months). Reversible, dose-limiting toxicities (DLTs) were observed in two patients at the 400mg dose-level, namely an asymptomatic Grade 3 amylase and lipase elevation and a Grade 3 headache with both patients subsequently resuming treatment with CYT387 at reduced doses.

The majority of patients experienced a rapid splenic response of a magnitude sufficient to encourage YM to increase the total number of 60 patients previously targeted to a maximum of 120 patients (subject to regulatory approval). This further expansion of the trial will allow exploration of the dose-dependency of the biological activity observed in the Phase I portion of the study. The expansion will also facilitate the collection of more safety and efficacy data at the two doses of interest (150 and 300mg) whilst also allowing detailed analysis of particular patient subsets.

Whereas the initial protocol measured spleen size reduction by palpation, MRI is proposed to be included in the expanded protocol to augment the clinical data set.

"We have continued to see very favorable biological activity data for CYT387, with disease-modifying effects comparable to other JAK2 inhibitors evident in my myelofibrosis patients, including significant spleen size reduction, improvement in constitutional symptoms and favorable hematological changes. The lack of patient withdrawal from the study is also testament to the tolerability and patient acceptability of this drug," said Dr. Ayalew Tefferi, Professor of Hematology at Mayo Graduate School and Chair of the study.

"We continue to be compelled by the early observations of activity and tolerability for CYT387," said Dr. Nick Glover, COO of YM BioSciences. "The Company remains on track to advance CYT387 towards an NDA-enabling study as early as 2011 and is reviewing opportunities for the compound in the numerous other indications in which evidence of activity has been shown with this family of molecules."

"This important deployment of resources to the JAK inhibitor program requires that we evaluate the allocation of our existing capital," said David Allan, Chairman and CEO, "As a consequence, we have decided to terminate further expenditures on the AeroLEF program at this time. We believe that CYT387 has the potential to be a competitive molecule across a spectrum of disorders, including indications in hematology, oncology and inflammatory diseases. As such, we are allocating our resources accordingly in order to maximize its preclinical and clinical development in the near term."

About CYT387:

CYT387 is a potent inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis. Typical myelofibrosis symptoms include an enlarged spleen, progressive anemia and poor overall survival.

    -   Potent, oral JAK1/2 inhibitor
    -   Excellent selectivity against a panel of over 150 structurally
        diverse protein kinases
    -   Excellent preclinical safety profile
    -   Direct preclinical comparison with other JAK2 inhibitors indicates
        that very few of the other compounds in development match the potency
        and selectivity of CYT387.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences Australia (formerly Cytopia Limited), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a JAK 1/2 small molecule inhibitor; and CYT997, a potent, vascular disrupting agent (VDA). YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM BioSciences Australia, include the JAK 1/2 inhibitor CYT387 and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr. Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... , ... Talon Innovations, a provider of Precision Machined Products and ... is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the ... Innovations was recognized as a nominee for this competitive award. , The “Best ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
Breaking Biology Technology:
... , ... , Formation of new blood ... been the focus of many drug screening and cell signaling research studies. Blood ... tumors, and is implicated in wound healing, retinopathy and macular degeneration. , ...
... , Tran T. Nham Varian Australia ... Introduction , Because ... with an ICP spectrometer, it has been widely used to determine trace ... work was to evaluate the ability of the ultrasonic nebulizer to handle ...
... Varian, Inc. , Introduction ... are veterinary drugs. The use of these in food production is ... and the European Union because of a possible increased cancer-risk through ... of nitrofurans contamination has been found in warm-water prawns, shrimp, and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 This ... dominate wearable technology products today, and emerging sensor types ... have risen through the peak of the wearable technology ... the slide to disillusionment. The common feature with all ... the key enabler for their most useful functions. Sensors ...
(Date:9/9/2015)... Columbia , Sept. 9, 2015  NuData ... organizational and solution-based milestones, furthering the company,s commitment ... of online fraud. NuData Security,s online ... enhancing the company,s growth cycle. The product combines ... to determine good user behavior from fraudulent behavior, ...
(Date:9/2/2015)... California , September 2, 2015 ... the security purpose implied in a system which ... geometry, voice, signature, iris, vein, DNA and finger ... has forced to develop such system which provides ... username, password, PIN, Patterns and tokens are vulnerable ...
Breaking Biology News(10 mins):
... MAMMALS could be at a greater risk of extinction due ... published today by the Zoological Society of London (ZSL). ... with information of where droughts and cyclones are most likely ... risk of exposure to extreme weather. The paper, published this ...
... WASHINGTON D.C. -- Secretary of Energy Steven Chu was among ... NSF,s Graduate Research Fellowship Program (GRFP) today. GRFP is ... engineering fields within NSF,s mission. It has been in ... in students with demonstrated potential for significant achievements in science ...
... synchronize their movements. For example, the footsteps of two ... consciously aware that it is happening. Similarly, the clapping ... Although this type of synchronous body movement has been ... social interactions remain obscure. In a new study, led ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: